Published in Lab Law Weekly, June 9th, 2006
Adventrx acquired all outstanding shares of SD Pharma, obtaining worldwide intellectual property rights, excluding rights for China, Taiwan, Hong Kong and Macau, to a portfolio of eight oncology and infectious disease therapeutic product candidates. These candidates include SDP-012 (ANX-530, vinorelbine emulsion), which was the subject of a prior license agreement between the companies, announced in October 2005.
Most of these SD Pharma compounds are novel nano-emulsion formulations of currently...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly